Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Stockholders' Equity (Deficit)

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2009	$ (9,869,852)		$ 80,937	$ 182,747,897	$ (192,698,686)
Balance, shares at Dec. 31, 2009			80,936,711
Issued restricted stock	660		660
Issued restricted stock, shares			660,000
Issued warrants in connection with consulting agreement	279,367			279,367
Cancelled restricted stock			(5)	5
Cancelled restricted stock, shares			(4,500)
Issued stock in payment of interest on convertible debt and dividends on convertible preferred stock	476,667		348	476,319
Issued stock in payment of interest on convertible debt and dividends on convertible preferred stock (in shares)	347,832		347,832
Issued stock in connection with stock purchase agreement, net of costs	777,458		661	776,797
Issued stock in connection with stock purchase agreement, net of costs (in shares)			660,541
Issued stock upon exercise of stock options, net	(63,705)		350	(64,055)
Issued stock upon exercise of stock options, net, shares	350,156		350,156
Issued Series B and Series C convertible preferred stock, net of costs	64,636,821	11		64,636,810
Issued Series B and Series C convertible preferred stock, net of costs (in shares)		11,000
Issued common stock and warrants in connection with direct offering, net of costs	4,309,951		3,158	4,306,793
Issued common stock and warrants in connection with direct offering, net of costs (in shares)			3,157,896
Issued stock to 401(k) plan	40,623		53	40,570
Issued stock to 401(k) plan, shares	53,499		53,499
Issued stock upon exercise of warrants, net	316,818		158	316,660
Issued stock upon exercise of warrants, net, shares			157,778
Effect of change in terms of warrants	800,878			800,878
Stock compensation expense	597,672			597,672
Preferred stock dividends	(8,206,745)				(8,206,745)
Net (loss) income	(49,964,868)				(49,964,868)
Balance at Dec. 31, 2010	4,131,745	11	86,320	254,915,713	(250,870,299)
Balance, shares at Dec. 31, 2010		11,000	86,319,913
Issued restricted stock	872		872
Issued restricted stock, shares			872,000
Issued warrants in connection with consulting agreement
Cancelled restricted stock	(596)		(686)	90
Cancelled restricted stock, shares			(686,000)
Issued stock upon exercise of stock options, net	(2,498,223)		1,832	(2,500,055)
Issued stock upon exercise of stock options, net, shares	1,832,673		1,832,673
Issued stock to 401(k) plan	61,971		35	61,936
Issued stock to 401(k) plan, shares	35,233		35,233
Issued stock upon exercise of warrants, net	8,327,190		4,027	8,323,163
Issued stock upon exercise of warrants, net, shares			4,026,552
Effect of change in terms of warrants	1,978,818			1,978,818
Conversion of Series B preferred stock to common stock		(1)	2,999	(2,998)
Conversion of Series B preferred stock to common stock, shares		(917)	2,998,590
Effect of beneficial conversion feature of promissory note	24,888			24,888
Stock compensation expense	3,592,090			3,592,090
Preferred stock dividends	(100,000)				(100,000)
Net (loss) income	5,612,992				5,612,992
Balance at Dec. 31, 2011	21,131,747	10	95,399	266,393,645	(245,357,307)
Balance, shares at Dec. 31, 2011		10,083	95,398,961
Issued restricted stock	455		455
Issued restricted stock, shares			455,000
Issued warrants in connection with consulting agreement
Cancelled restricted stock	(596)		(601)	5
Cancelled restricted stock, shares			(600,500)
Issued stock upon exercise of stock options, net	743,295		1,226	742,069
Issued stock upon exercise of stock options, net, shares	1,225,270		1,225,271
Cancelled stock upon repurchase from executives	(100,875)		(37)	(100,838)
Cancelled stock upon repurchase from executives, shares			(37,500)
Issued stock to 401(k) plan	50,272		17	50,255
Issued stock to 401(k) plan, shares	17,390		17,390
Issued stock upon exercise of warrants, net	1,978,601		6,020	1,972,581
Issued stock upon exercise of warrants, net, shares			6,020,000
Effect of change in terms of warrants	496,671			496,671
Conversion of Series B preferred stock to common stock		(2)	7,014	(7,012)
Conversion of Series B preferred stock to common stock, shares		(2,145)	7,014,150
Conversion of Series C preferred stock to common stock		(1)	3,226	(3,225)
Conversion of Series C preferred stock to common stock, shares		(1,000)	3,226,000
Short-swing profit returned to the Company	45,473			45,473
Issued stock for payment of sublicense fee	1,146,000		300	1,145,700
Issued stock for payment of sublicense fee , shares	300,000		300,000
Stock compensation expense	2,304,118			2,304,118
Preferred stock dividends	(43,333)				(43,333)
Net (loss) income	(29,157,204)				(29,157,204)
Balance at Dec. 31, 2012	$ (1,405,376)	$ 7	$ 113,019	$ 273,039,442	$ (274,557,844)
Balance, shares at Dec. 31, 2012		6,938	113,018,772